• 1
    Bergmann M,Blasius S,Bankfalvi A,Mellin W. Primary non-Hodgkin lymphomas of the CNS-proliferation, oncoproteins and Epstein-Barr-virus. Gen Diagn Pathol. 1996; 141: 235242.
  • 2
    Larocca LM,Capello D,Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998; 92: 10111019.
  • 3
    Camilleri-Broet S,Martin A,Moreau A, et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol. 1998; 110: 607612.
  • 4
    Hermine O,Haioun C,Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 1996; 87: 265272.
  • 5
    Gascoyne RD,Adomat SA,Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997; 90: 244251.
  • 6
    Barrans SL,Carter I,Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002; 99: 11361143.
  • 7
    Ichikawa A,Kinoshita T,Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med. 1997; 337: 529534.
  • 8
    Sohn SK,Jung JT,Kim DH, et al. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol. 2003; 73: 101107.
  • 9
    Jerkeman M,Anderson H,Dictor M, et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study. Ann Hematol. 2004; 83: 414419.
  • 10
    Miller TP,Grogan TM,Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994; 83: 14601466.
  • 11
    Rosenwald A,Wright G,Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 19371947.
  • 12
    Alizadeh AA,Eisen MB,Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503511.
  • 13
    Chang CC,McClintock S,Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol. 2004; 28: 464470.
  • 14
    Colomo L,Lopez-Guillermo A,Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003; 101: 7884.
  • 15
    Hans CP,Weisenburger DD,Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275282.
  • 16
    Ferreri AJ,Blay JY,Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003; 21: 266272.
  • 17
    Bessell EM,Graus F,Lopez-Guillermo A, et al. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys. 2004; 59: 501508.
  • 18
    Krogh-Jensen M,Johansen P,D'Amore F. Primary central nervous system lymphomas in immunocompetent individuals: histology, Epstein-Barr virus genome, Ki-67 proliferation index, p53 and bcl-2 gene expression. Leuk Lymphoma. 1998; 30: 131142.
  • 19
    Hayashi Y,Iwato M,Arakawa Y, et al. Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. J Neurooncol. 2001; 55: 5158.
  • 20
    Braaten KM,Betensky RA,de Leval L, et al. Bcl-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003; 9: 10631069.
  • 21
    Lin CH,Kuo KT,Chuang SS, et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res. 2006; 12: 11521156.
  • 22
    Sugita Y,Tokunaga O,Nakashima A,Shigemori M. SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts. Pathol Int. 2004; 54: 659666.
  • 23
    Camilleri-Broet S,Criniere E,Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006; 107: 190196.
  • 24
    Montesinos-Rongen M,Kuppers R,Schluter D, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol. 1999; 155: 20772086.
  • 25
    Thompsett AR,Ellison DW,Stevenson FK,Zhu D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood. 1999; 94: 17381746.
  • 26
    Sekita T,Tamaru JI,Kaito K, et al. Primary central nervous system lymphomas express Vh genes with intermediate to high somatic mutations. Leuk Lymphoma. 2001; 41: 377385.
  • 27
    Lossos IS,Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 9951007.